Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Sees A Path Forward For Xarelto In Post-Hospital VTE Despite MARINER Failure

Executive Summary

The company says the MARINER data combined with prior MAGELLAN results in acute medically ill patients support prophylaxis for VTE following a hospital stay in select individuals. However, there is no regulatory path forward in heart failure based on the COMMANDER HF study.

You may also be interested in...

Bayer/J&J contemplate edge of the earth in VTE as MAGELLAN scuppers Xarelto

Bayer and Johnson & Johnson's attempts the circumnavigate the world of venous thromboembolism (VTE) prevention with their oral Factor Xa inhibitor Xarelto (rivaroxaban) have hit an unexpected setback in the MAGELLAN study of medically ill patients.

CFO Joshua Smiley On Lilly’s Next Decade Of Growth

Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development. 

Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race

Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts